

# Application of the Free-Wilson Technique to Structurally Related Series of Homologues. Quantitative Structure-Activity Relationship Studies of Narcotic Analgetics

Robert Katz,\* Steven F. Osborne, and Florin Ionescu

Biomedical Sciences Division, Mid-Atlantic Research Institute, Bethesda, Maryland 20014. Received December 1, 1976

A series of benzomorphans with ED<sub>50</sub> values determined in vivo by the hot-plate method in mice is analyzed by the modified Free-Wilson method. The QSAR yields 36 substituent constants ( $a_i$ ) with contributions to the overall activity in agreement with experimental data. Substituent constant values obtained for benzomorphans are used in calculating log (1/C) values for six morphinans. An excellent correlation is obtained ( $r = 0.95$ ) between the six calculated and observed activities. The possibility of extending the Free-Wilson approach from one series of homologues to another is demonstrated.

The mathematical model of Free and Wilson<sup>1</sup> (F-W) for quantitative structure-activity relationships (QSAR) has seen only moderate use since its introduction.<sup>2-13</sup> Recent studies, however, have demonstrated its utility, especially when combined with or followed by a Hansch<sup>14-16</sup> or Boček-Kopecký<sup>17,18</sup> analysis. The F-W technique is particularly suited to the case when hydrophobic, electronic, and steric parameters are not readily available. Experimental determination of such parameters for narcotic analgetics of the morphine, morphinan, and benzomorphan series would be a monumental task. However, lack of ample biological activity data and/or multiple occurrences for substituents in a series of drugs limits the applicability of the F-W method. These limitations might be surmounted if results from a F-W analysis of one series could be extended to a structurally similar homologous series of drugs. Therefore, we applied the F-W type QSAR to the structurally simple benzomorphans (see Table I for structure) and extrapolated the results from this series to the homologous, structurally more complex, morphinan series (see Table V for structure).

**Methods.** The F-W additivity model is based on the assumption that a particular substituent group which appears at the same position in the molecule will contribute a constant entity to (or subtract it from) the overall biological activity. This entity is quantitated as a substituent constant and is independent of physical parameters of the related compounds.

In our analysis the modified F-W approach developed by Cammarata and You<sup>7</sup> and Fujita and Ban<sup>8</sup> was used. This approach is based upon eq 1 where  $a_i$  = contribution

$$\log (1/C) = \sum_i a_i x_i + \mu \quad (1)$$

of substituent  $i$ , with  $a_H = 0$  (by definition),  $x_i = 1$  or 0 depending upon the presence or absence of the  $i$ th substituent, and  $\mu = \log (1/C)_{\text{calcd}}$  for the unsubstituted compound.<sup>12</sup> The compound bearing only hydrogens is entered into the matrix with biological activity = log (1/C) and  $x_i = 0$  for  $i = H$  at all substituted positions included in the analysis. No symmetry equations are required.<sup>8</sup> A standard multiple regression program, BMD02R, that solves the input equations by matrix inversion was used. The  $F$  level for inclusion of variables was set equal to zero. Most of the relevant statistics, including the correlation coefficient ( $r$ ), the standard deviation ( $s$ ), the  $F$  statistic, and the correlation and covariance matrices are routinely computed with the program.

The benzomorphan biological test data were obtained from a NIH computer record system compiled by Jacobson and Kaufmann.<sup>19,20</sup> The data consist of ED<sub>50</sub> values determined on Caesarian-derived general purpose mice<sup>21</sup> by

the Eddy-Leimbach hot-plate technique.<sup>22</sup> Each compound was tested on at least 12 mice with the resulting ED<sub>50</sub> in mg/kg determined by probit analysis. Morphinan biological test data were obtained from ref 23 and were determined by the same Eddy-Leimbach technique. All values were converted to the usual log (1/C), where  $C$  = mol/kg of test animal.

## Results

Ninety-nine benzomorphans substituted at five positions and possessing 36 different substituents are listed in Table I. Compounds 1-70 include the biologically more active levorotatory (-) isomers or racemic mixtures ( $\pm$ ) and contain substituents with two or more occurrences. Compounds 71-86 are similar (-) isomers and racemates; however, they possess a substituent with one occurrence. Compounds 87-99 are the biologically less active dextrorotatory (+) isomers. All of these have their enantiomer present among compounds 1-70. "Substituents" 37 and 38 distinguish between enantiomers.

Substituent constants ( $a_i$ ) resulting from the solution of three matrices consisting of compounds 1-99, 1-86, and 1-70 are presented in Table II. The  $a_i$  values derived in each analysis are all referenced to  $a_H = 0$ . Craig<sup>9</sup> has shown that differences between the additive constants at each position can be checked for statistical significance through  $t$  tests.<sup>24</sup> The absence of a significant  $t$  test for a certain  $a_i$  does not mean a lack of statistical significance for the particular  $a_i$ ; it only means that the difference between the  $a_i$  and  $a_H = 0$  is not significant.

Kubinyi and Kehrhaan have noted that the Fujita-Ban modification is a simple linear transformation of the classical F-W model.<sup>12</sup> In order to validate this for the standard multiple regression program used in our analysis, restrictive equations were incorporated into the matrix. The results of this analysis are found in Table II. Although the  $a_i$  and regression constant ( $\mu$ ) are different, subtraction of  $a_H$  at a position from the  $a_i$  of a substituent at that position will yield the  $a_i$  of the substituent when  $a_H = 0$ . Slight differences due to rounding are seen, but  $r$ ,  $s$ , and  $F$  are identical. The statistics for the regressions are presented in Table III. They prove that the correlations obtained are significant at the 1% level. The explained variance (EV)<sup>25</sup> for the regression on compounds 1-70 was EV = 0.674.

## Discussion and Application

For the matrix of 99 compounds, it is interesting to note the  $a_i$  values (Table II) for the (+) and (-) "substituents". The (+)  $a_i$  value of -0.968 is different from zero at the 5% level by the  $t$  test. This reflects the experimental finding that the dextro isomers are less active than the racemate or levo isomers in the benzomorphan series.<sup>26</sup> It is also known that the levo isomers are slightly more active than

The diagram shows a chemical structure of a substituted indole derivative. The indole ring system is numbered 1 through 9. Substituents are indicated as follows:  $R_1$  at position 3,  $R_2$  at position 1,  $R_3$  at position 9,  $R_4$  at position 8, and  $R_5$  at position 5. The benzene ring is also numbered with primes: 1', 2', 3', 4', 6', and 7'.

[illegible]

[illegible]

Table I (Continued)

Compd no.	Substituent number																																						Log (1/C) <sub>obsd</sub> <sup>b</sup>	Log (1/C) <sub>pred</sub> <sup>f</sup>					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38							
90	1															1																									1	1.79	2.18		
91							1				1																																1.62	0.92	
92		1																																										1.60	1.62
93 <sup>e</sup>																		1																										1.51	1.48
94																																												1.38	1.49
95																																												1.31	1.90
96																																												1.22	1.09
97																																												1.20	1.31
98																																												1.04	1.20
99																																												1.03	1.38

<sup>a</sup> R<sub>4</sub> is presented before R<sub>5</sub> to maintain an initial numbering system. <sup>b</sup> Log (1/C)<sub>obsd</sub> values were computed on a molar basis using salt form information supplied by Dr. A. E. Jacobson. <sup>c</sup> Average of 7907 (log 1/C = 2.85) and 7569 (log 1/C = 2.57), which are the same compound but different salt forms. <sup>d</sup> Average of 8178 (log 1/C = 2.40) and 8320 (log 1/C = 2.30) (different salt forms). <sup>e</sup> Average of 8194 (log 1/C = 1.58) and 8323 (log 1/C = 1.43) (different salt forms). <sup>f</sup> Predicted log 1/C values calculated from eq 1 using *a<sub>i</sub>* of 99 compound set from Table II.

the racemate, and this is seen in the *a<sub>i</sub>* value of the (-) "substituent" (0.173 referenced to *a<sub>i</sub>*(±) = 0). Since 13 pairs of enantiomers are included in this matrix, double weighting of substituents 1-36 could lead to distortion of their *a<sub>i</sub>* values. Inclusion of compounds 71-86<sup>27</sup> (Table I) could result in misleading statistics since they yield single-point determinations.

A matrix of 70 compounds is obtained when dextro isomers (87-99) and compounds with single-occurring substituents (71-86) are deleted from the original 99-compound matrix. Examination of the *a<sub>i</sub>* values at the individual positions reveals the interesting points outlined below.

For substituent R<sub>1</sub> it is known that the order of analgesic activity is H < OCH<sub>3</sub> < OCOCH<sub>3</sub> ≈ OH. Our *a<sub>i</sub>* values bear out this relationship: *a<sub>H</sub>* = 0, *a<sub>POCH<sub>3</sub></sub>* = 0.349, *a<sub>OCOCH<sub>3</sub></sub>* = 0.923, and *a<sub>OH</sub>* = 0.984.<sup>28</sup> The *t* tests indicate that the *a<sub>OH</sub>* and *a<sub>OCOCH<sub>3</sub></sub>* are different from the *a<sub>POCH<sub>3</sub></sub>* at the 5 and 10% level, respectively: *t<sub>OH</sub>* = 2.22, *t<sub>0.05</sub>*<sup>(43)</sup> = 2.01, *t<sub>OCOCH<sub>3</sub></sub>* = 1.92, *t<sub>0.10</sub>*<sup>(18)</sup> = 1.73. Experimental ED<sub>50</sub> values suggest that the nicotinolyloxy substituent is less active than a free hydroxyl. Although this is not reflected in our *a<sub>i</sub>*, a *t* test established no difference between the *a<sub>OCOAr(3-C<sub>5</sub>H<sub>4</sub>N)</sub>* and the *a<sub>OH</sub>* at the 10% level: *t<sub>OCOAr(3-C<sub>5</sub>H<sub>4</sub>N)</sub>* = 0.46, *t<sub>0.10</sub>*<sup>(33)</sup> = 1.69. This indicates the desirability of performing a statistical test before drawing conclusions about substituents with few occurrences.

For substituent R<sub>2</sub> there are three *a<sub>i</sub>* values significantly different from zero. The order of activity at this position is H < CH<sub>3</sub> ≈ CH<sub>2</sub>CH<sub>2</sub>CO(C<sub>6</sub>H<sub>5</sub>) < CH<sub>2</sub>CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>).<sup>26</sup> This order is reflected by our values: *a<sub>H</sub>* = 0, *a<sub>CH<sub>3</sub></sub>* = 0.924, *a<sub>CH<sub>2</sub>CH<sub>2</sub>CO(C<sub>6</sub>H<sub>5</sub>)</sub>* = 1.10, and *a<sub>CH<sub>2</sub>CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)</sub>* = 1.62. In spite of multiple occurrences for CH<sub>3</sub> and CH<sub>2</sub>CH<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>), a *t* test did not establish a difference between *a<sub>CH<sub>2</sub>CH<sub>2</sub>CO(C<sub>6</sub>H<sub>5</sub>)</sub>* and *a<sub>CH<sub>3</sub></sub>* at the 10% level: *t<sub>CH<sub>2</sub>CH<sub>2</sub>CO(C<sub>6</sub>H<sub>5</sub>)</sub>* = 0.91, *t<sub>0.10</sub>*<sup>(60)</sup> = 1.67.

Positions R<sub>3</sub> (9α) and R<sub>4</sub> (9β) can be examined together. Compounds with alkyl substituents at C-9 oriented away from nitrogen (9α) are generally less effective than those in which the same substituent is oriented toward the N ring (9β).<sup>26</sup> This relationship is observed here, as at R<sub>3</sub>, *a<sub>CH<sub>3</sub></sub>* = 0.204, *a<sub>CH<sub>2</sub>CH<sub>3</sub></sub>* = 0.0350, while at R<sub>4</sub> *a<sub>CH<sub>3</sub></sub>* = 0.486, *a<sub>CH<sub>2</sub>CH<sub>3</sub></sub>* = 0.172.

Also of interest is the negative coefficient of OH at both the 9α and 9β positions. The 9α *a<sub>OH</sub>* is significantly different from zero at the 5% level, *t<sub>9α-OH</sub>* = 3.98, *t<sub>0.05</sub>*<sup>(85)</sup> = 1.99, but the 9β *a<sub>OH</sub>* is significantly different from zero only at the 10% level, *t<sub>9β-OH</sub>* = 1.94, *t<sub>0.10</sub>*<sup>(85)</sup> = 1.67. The negative effect of the 9α- or 9β-OH on analgesic activity has been documented.<sup>26,29,30</sup>

Three alkyl and one phenyl group are substituted on R<sub>5</sub>. None of their *a<sub>i</sub>* values are significantly different from zero at the 5% level.

As previously described by Craig<sup>31</sup> the range of *a<sub>i</sub>* at each position can help identify those positions most sensitive to change in substituent. By studying the range of *a<sub>i</sub>* at R<sub>1</sub>-R<sub>5</sub>, we note that the nitrogen position (R<sub>2</sub>) and aromatic ring position (R<sub>1</sub>) are the sites most sensitive to substitution, followed by the 9β (R<sub>4</sub>) and 9α (R<sub>3</sub>) positions. It appears that the C-5 position (R<sub>5</sub>) is the least sensitive to the effect of substitution on biological activity. The major importance of R<sub>2</sub> and R<sub>1</sub> in the determination of biological activity has been well documented.<sup>32</sup>

Data allowing an evaluation of the qualitative value of single-occurring substituents (compounds 1-86 in Table II) are presented in Table IV. The *a<sub>i</sub>* values obtained are parallel to the experimental parameter, Δ

$$\Delta = \log (1/C)_{\text{obsd (single-point compound)}} - \log (1/C)_{\text{obsd (analogous H compound)}}$$

Table II. Substituent Constants ( $a_i$ )

Position	No.	Substituent	Compds 1-99		Compds 1-86		Compds 1-70			Compds 1-70 using restrictive eq	
			$a_i$	$n^a$	$a_i$	$n$	$a_i$	$n$	Range <sup>b</sup>	$a_i$	$n$
R <sub>1</sub>	9	OCOAr(3-C <sub>5</sub> H <sub>4</sub> N)	1.49 <sup>c</sup>	2	1.69 <sup>c</sup>	2	1.694 <sup>c</sup>	2		1.02 <sup>c</sup>	2
	3	OCOCH <sub>3</sub>	0.869 <sup>c</sup>	8	0.923 <sup>c</sup>	8	0.923 <sup>c</sup>	8		0.246 <sup>c</sup>	8
	2	OH	0.803 <sup>c</sup>	51	0.984 <sup>c</sup>	40	0.984 <sup>c</sup>	33		0.307 <sup>c</sup>	33
	4	OCOCH <sub>2</sub> CH <sub>3</sub>	0.612	1	0.641	1					
	5	OCOCH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	0.552	1	0.581	1					
	6	OCOCH <sub>2</sub> (CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	0.367	1	0.729	1					
	7	OCH <sub>3</sub>	0.239	13	0.349	12	0.349	12		-0.328	12
		H	0	19	0	18	0	15		-0.676	15
	8	NO <sub>2</sub>	-0.108	1	0.036	1					
	1	F	-0.454	1	-0.463	1					
R <sub>2</sub>	10	Cl	-0.704	1	-0.713	1			1.69		
	14	CH <sub>2</sub> CH <sub>2</sub> Ar(2-C <sub>4</sub> H <sub>3</sub> S)	2.54 <sup>c</sup>	1	2.44 <sup>c</sup>	1					
	12	CH <sub>2</sub> CH <sub>2</sub> (C <sub>6</sub> H <sub>5</sub> )	1.58 <sup>c</sup>	13	1.62 <sup>c</sup>	12	1.62 <sup>c</sup>	12		0.658 <sup>c</sup>	12
	17	CH <sub>2</sub> -c-(C <sub>3</sub> H <sub>3</sub> )CH <sub>2</sub>	1.53 <sup>c</sup>	2	2.14 <sup>c</sup>	1					
	13	CH <sub>2</sub> CH <sub>2</sub> CO(C <sub>6</sub> H <sub>5</sub> )	1.11 <sup>c</sup>	2	1.10 <sup>c</sup>	2	1.10 <sup>c</sup>	2		0.136 <sup>c</sup>	2
	11	CH <sub>3</sub>	0.835 <sup>c</sup>	75	0.924 <sup>c</sup>	64	0.924 <sup>c</sup>	50		-0.039	50
	15	CH <sub>2</sub> -c-(C <sub>3</sub> H <sub>5</sub> )	0.133	2	0.022	2	0.022	2		-0.941	2
		H	0	2	0	2	0	2		-0.963	2
	16	CH <sub>2</sub> CHC(CH <sub>3</sub> ) <sub>2</sub>	-0.414	2	-0.242	2	-0.242	2	1.86	-1.20	2
	26	CH <sub>3</sub>	0.166	26	0.204	24	0.204	21		0.250	21
R <sub>3</sub>	24	CH <sub>2</sub> CH <sub>3</sub>	0.103	12	0.035	8	0.035	6		0.081	6
		H	0	46	0	39	0	28		0.046	28
	23	OCOCH <sub>3</sub>	-0.037	6	-0.078	6	-0.078	6		-0.032	6
	25	OH	-0.729 <sup>c</sup>	9	-0.809 <sup>c</sup>	9	-0.809 <sup>c</sup>	9	1.01	-0.762 <sup>c</sup>	9
	21	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	0.586	1	0.507	1					
R <sub>4</sub>	19	CH <sub>2</sub> CH <sub>3</sub>	0.518	4	0.712 <sup>c</sup>	3	0.712 <sup>c</sup>	3		0.612 <sup>c</sup>	3
	18	CH <sub>3</sub>	0.433 <sup>c</sup>	19	0.486 <sup>c</sup>	17	0.486 <sup>c</sup>	16		0.385 <sup>c</sup>	16
		H	0	67	0	57	0	44		-0.100	44
	20	OH	-0.318	7	-0.412	7	-0.412	7	1.12	-0.512	7
	22	CH <sub>2</sub> OH	-0.552	1	-0.703	1					
R <sub>5</sub>	33	C <sub>6</sub> H <sub>5</sub>	0.552	7	0.336	5	0.336	4		0.180	4
	35	OCOCH <sub>3</sub>	0.385	1	0.411	1					
	28	CH <sub>2</sub> CH <sub>3</sub>	0.290	26	0.239	21	0.239	19		0.083	19
	29	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	0.236	8	0.160	7	0.160	6		0.004	6
	36	OCOCH <sub>2</sub> CH <sub>3</sub>	0.175	1	0.201	1					
	27	CH <sub>3</sub>	0.114	47	0.110	43	0.110	37	0.336	-0.046	37
	30	CH <sub>2</sub> (CH <sub>2</sub> ) <sub>2</sub> CH <sub>3</sub>	0.112	1	-0.043	1					
		H	0	5	0	4	0	4		-0.156	4
	31	CH <sub>2</sub> (CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	-0.098	1	-0.253	1					
	34	OH	-0.505	1	-0.479	1					
Isomer <sup>d</sup>	32	CH <sub>2</sub> (CH <sub>2</sub> ) <sub>4</sub> CH <sub>3</sub>	-0.528	1	-0.683	1					
	37	(+)	-0.968	13							
	38	(±)	0	65							
		(-)	0.173	21							

<sup>a</sup> Number of occurrences. <sup>b</sup> The range is computed by subtracting the lowest  $a_i$  at a position from the highest  $a_i$  at that position; the ranges shown refer to  $a_i$  derived from compounds 1-70. <sup>c</sup> These values denote a significant difference (5% level) between an  $a_i$  value and the  $a_H$  value at that position. <sup>d</sup> Just as hydrogen is eliminated as a substituent at each position in the matrix in Table I, the (±) "substituent" is eliminated and  $a_{(±)}$  is set equal to zero.

Table III. Statistics from Free-Wilson Analysis of 6,7-Benzomorphans

Compds analyzed	No. of compds $n$	Correlation coeff $r$	Standard deviation $s$	Regression constant $\mu^a$	$F$ statistic from regression	Critical $F$ at 1% level
1-99	99	0.893	0.466	0.420	6.23	$F_{38,60} = 1.95$
1-86	86	0.909	0.457	0.305	6.45	$F_{36,49} = 2.09$
1-70	70	0.879	0.457	0.305	8.35	$F_{20,49} = 2.27$
1-70 <sup>b</sup>	70	0.8	0.457	2.15	8.35	$F_{20,49} = 2.27$

<sup>a</sup> Computed from the expression  $\mu = \log (1/C)_{\text{obsd mean}} - \sum_{i=1}^q a_i \bar{x}_i$ , where  $a_i$  = substituent constant for substituent  $x_i$ ,  $\bar{x}_i$  = mean value for substituent  $x_i$ , and  $q$  = number of substituents. With the modified Free-Wilson,  $\bar{x}_i$  = (number of occurrences)/(number of compounds); when restrictive equations are used  $\bar{x}_i = 0$ . <sup>b</sup> Using restrictive equations.

Table IV. Evaluation of  $a_i$  for Single-Point Substituents

Substituent position	Compd no.	Single-point substituent	$\Delta^{a,b}$	Substituent constant
R <sub>1</sub>	76 <sup>c</sup>	OCOCH <sub>2</sub> CH <sub>3</sub>	0.65	0.64
	78 <sup>c</sup>	OCOCH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	0.59	0.58
	84 <sup>d</sup>	F	-0.19	-0.46
	85 <sup>d</sup>	Cl	-0.44	-0.71
R <sub>4</sub>	73 <sup>e</sup>	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	0.45	0.51
R <sub>5</sub>	79 <sup>f</sup>	OCOCH <sub>3</sub>	0.34	0.41
	83 <sup>f</sup>	OCOCH <sub>2</sub> CH <sub>3</sub>	0.13	0.20
	86 <sup>f</sup>	OH	-0.55	-0.48

<sup>a</sup>  $\Delta = \log (1/C)_{\text{obsd (single-point compound)}} - \log (1/C)_{\text{obsd (hydrogen analogue)}}$  (where the hydrogen analogue refers to replacement of the single-occurring substituent by hydrogen). <sup>b</sup>  $\Delta$  values for single-occurring substituents [R<sub>1</sub> = OCOCH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, NO<sub>2</sub>; R<sub>2</sub> = CH<sub>2</sub>CH<sub>2</sub>(2-C<sub>4</sub>H<sub>9</sub>S), CH<sub>2</sub>-c-(C<sub>3</sub>H<sub>7</sub>)CH<sub>2</sub>; R<sub>4</sub> = CH<sub>2</sub>OH; R<sub>5</sub> = CH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>, CH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>] cannot be calculated due to lack of a hydrogen reference compound. <sup>c</sup> Compound 59 used as reference. <sup>d</sup> Compound 62 used as reference. <sup>e</sup> Compound 28 used as reference. <sup>f</sup> Compound 61 used as reference.

for all single-point substituents from this table.

Single-occurring substituents CH<sub>2</sub>CH<sub>2</sub>(2-C<sub>4</sub>H<sub>9</sub>S) and CH<sub>2</sub>-c-(C<sub>3</sub>H<sub>7</sub>)CH<sub>2</sub> are statistically different from zero at the 5% level. Although analogous hydrogen compounds are not available for reference, the extreme activity of CH<sub>2</sub>CH<sub>2</sub>(2-C<sub>4</sub>H<sub>9</sub>S) has been noted.<sup>26</sup>

We attempted to extend the use of  $a_i$  values determined from compounds in the benzomorphan series to the morphinan series. We identified a group of morphinans (Table V) with substituents at R<sub>1</sub> and R<sub>2</sub> for which  $a_i$  values were obtained in the benzomorphan series. The activity contribution of the cyclohexyl ring formed from C<sub>5-8,13,14</sub> was approximated with the  $a_i$  values of ethyl groups at R<sub>3</sub> and R<sub>5</sub> in benzomorphans. The extension was made by comparing observed activities with calculated

activities for morphinans. Calculated activities are computed using eq 2. A sample morphinan activity

$$\log (1/C)_{\text{calcd (morphinan)}} = \sum_i a_{i(\text{benzomorphan})} + \mu_{\text{benzomorphan}} \quad (2)$$

calculation is given in eq 3 for compound 3' (Table V) using benzomorphan  $a_i$  (compounds 1-86, Table II);  $\mu$  is taken from the regression on compounds 1-86 (Table III). Log

$$\begin{aligned} \log (1/C)_{\text{calcd (morphinan)}} &= a_{R_1=\text{OH}} + a_{R_2=\text{CH}_3} + \\ & a_{R_3=\text{CH}_2\text{CH}_3} + a_{R_4=\text{H}} + a_{R_5=\text{CH}_2\text{CH}_3} + \mu = \\ & 0.984 + 0.924 + 0.035 + 0 + 0.239 + \\ & 0.305 = 2.49 \end{aligned} \quad (3)$$

(1/C) values calculated this way for morphinans 3' and 4' are identical with log (1/C) values calculated for benzomorphans 30 and 22, respectively, from Table I. For morphinans 1', 2', 5', and 6' we could not identify corresponding benzomorphans with known analgesic activity. Therefore, the above calculations were based on the assumption that identical substituents at R<sub>1</sub> and R<sub>2</sub> in benzomorphans and morphinans possess very similar contributions to the biological activity.

A plot of observed activities vs. calculated activities is shown in Figure 1. The regression equation (eq 4) correlating log (1/C)<sub>obsd</sub> with log (1/C)<sub>calcd</sub> for the six morphinans was obtained from Figure 1. The correlation is

$$\begin{aligned} \log (1/C)_{\text{obsd}} &= 0.769 (\pm 0.351) \log (1/C)_{\text{calcd}} + \\ & 4.05 (\pm 1.019) \end{aligned} \quad (4)$$


$n = 6, r = 0.95, s = 0.254$

significant at the 1% level with  $F = 37.1$  and  $EV = 0.878$ . The presence of a positive intercept in Figure 1 could be due to the introduction of  $a_{\text{CH}_2\text{CH}_3}$  at R<sub>3</sub> and R<sub>5</sub> which underestimates the activity contribution of the cyclohexyl ring.<sup>33</sup>

Table V. Comparison of Morphinan Log (1/C)<sub>obsd</sub> with Biological Activities Calculated by Use of Benzomorphan,  $a_i$ 

Compd no.	Substituents <sup>a</sup>		Log (1/C) <sub>calcd</sub> <sup>b</sup>	Log (1/C) <sub>obsd</sub> <sup>c</sup>	Log (1/C) <sub>pred</sub> <sup>d</sup>
	R <sub>1</sub>	R <sub>2</sub>			
1'	OH	CH <sub>2</sub> CH=C(CH <sub>3</sub> ) <sub>2</sub>	1.33	5.32	5.07
2'	OCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> (C <sub>6</sub> H <sub>5</sub> )	2.56	5.72	6.02
3'	OH	CH <sub>3</sub>	2.49	5.73	5.96
4'	OH	CH <sub>2</sub> CH <sub>2</sub> (C <sub>6</sub> H <sub>5</sub> )	3.19	6.49	6.50
5'	OCOCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> (C <sub>6</sub> H <sub>5</sub> )	3.13	6.64	6.46
6'	OH	CH <sub>2</sub> CH <sub>2</sub> (2-C <sub>4</sub> H <sub>9</sub> S)	4.01	7.27	7.13

<sup>a</sup> For the purpose of calculating activities R<sub>3</sub> = CH<sub>2</sub>CH<sub>3</sub>, R<sub>4</sub> = H, and R<sub>5</sub> = CH<sub>2</sub>CH<sub>3</sub> in all morphinans listed (see eq 2). <sup>b</sup> Calculated by use of eq 3. <sup>c</sup> Values taken from ref 23. <sup>d</sup> Calculated by use of regression eq 4.






Figure 1. Observed activities vs. Free-Wilson-derived calculated activities for six morphinans.

It appears from above that, in vivo, the contribution of the cyclohexyl ring is a constant entity for the morphinans studied. An average "cyclohexyl" = 3.41 has been calculated from data in Table V. This "apparent" substituent constant value could be used to further the extension to an additional homologous series (i.e., morphines).

Hansch implies that two classes of compounds have similar modes of action if they yield comparable regression equations.<sup>34,35</sup> Our study suggests that if  $a_i$  determined from one series of compounds can be successfully extended to another series, then the two series may act similarly at the molecular level. A lack of correlation may indicate a dissimilar mode of action.

**Acknowledgment.** This investigation was supported by Grant DA 01037 from the National Institute on Drug Abuse. We wish to thank Dr. R. Willette for his encouragement, Dr. A. E. Jacobson for his help in providing the NIH files and his advice concerning biological data, and Dr. M. B. Hidalgo for his help in adapting the computer programs. We also wish to thank Drs. P. Craig, A. Cammarata, and P. Andrulis for helpful comments.

## References and Notes

- (1) S. M. Free, Jr., and J. W. Wilson, *J. Med. Chem.*, **7**, 395 (1964).
- (2) W. P. Purcell, *Biochim. Biophys. Acta*, **105**, 201 (1965).
- (3) J. G. Beasley and W. P. Purcell, *Biochim. Biophys. Acta*, **178**, 175 (1969).
- (4) W. P. Purcell and J. M. Clayton, *J. Med. Chem.*, **11**, 199 (1968).
- (5) T. Ban and T. Fujita, *J. Med. Chem.*, **12**, 353 (1969).
- (6) J. M. Clayton and W. P. Purcell, *J. Med. Chem.*, **12**, 1987 (1969).
- (7) A. Cammarata and S. J. You, *J. Med. Chem.*, **13**, 93 (1970).
- (8) T. Fujita and T. Ban, *J. Med. Chem.*, **14**, 148 (1971).
- (9) P. N. Craig, *J. Med. Chem.*, **15**, 144 (1972).
- (10) P. N. Craig and C. Hansch, *J. Med. Chem.*, **16**, 661 (1973).
- (11) A. Cammarata, *J. Med. Chem.*, **15**, 573 (1972).
- (12) H. Kubinyi and O. Kehrhaun, *J. Med. Chem.*, **19**, 578 (1976).
- (13) H. Kubinyi, *J. Med. Chem.*, **19**, 587 (1976).
- (14) C. Hansch and T. Fujita, *J. Am. Chem. Soc.*, **86**, 1616 (1964).
- (15) C. Hansch, *Acc. Chem. Res.*, **2**, 232 (1969).
- (16) C. Hansch in "International Encyclopedia of Pharmacology and Therapeutics", Sect. 5, Vol. 1, C. J. Cavallito, Ed., Pergamon Press, New York, N.Y., 1973, p 75.
- (17) K. Boček, J. Kopecký, M. Krivucova, and D. Vlachova, *Experientia*, **20**, 667 (1964).
- (18) J. Kopecký, K. Boček, and D. Vlachova, *Nature (London)*, **207**, 981 (1965).
- (19) Biological test data were compiled, arranged, and placed on a public computer record file at NIH by A. E. Jacobson (NIAMDD) and J. Kaufmann (DCRT) in Nov 1970.
- (20) S. J. Kaufmann, A. E. Jacobson, and W. F. Raub, *J. Chem. Doc.*, **10**, 248 (1970).
- (21) A. E. Jacobson and E. L. May, *J. Med. Chem.*, **8**, 563 (1965), and references cited therein.
- (22) N. B. Eddy and D. Leimbach, *J. Pharmacol. Exp. Ther.*, **107**, 385 (1953).
- (23) N. B. Eddy and E. L. May, "Synthetic Analgesics", Part IIB, Pergamon Press, New York, N.Y., 1966, pp 76-91.
- (24) G. W. Snedecor and W. G. Cochran, "Statistical Methods", 6th ed, Iowa State University Press, Ames, Iowa, 1967, p 381.
- (25) EV is calculated according to the expression  $EV = [\Sigma d^2 / (n - k)] / [\Sigma y^2 / (n - 1)]$  where  $d = \log (1/C)_{\text{obsd}} - \log (1/C)_{\text{calcd}}$ ,  $y = \log (1/C)_{\text{obsd}} - \log (1/C)_{\text{mean obsd}}$ ,  $k$  = number of parameters (including  $\mu$ ), and  $n$  = number of compounds. For further details see ref 24.
- (26) Reference 23, p 141.
- (27) Compound 72 contains substituent 17 at  $R_2$ . This substituent is also present in compound 90, which is a dextro isomer. Deletion of the dextro isomers will then lead to a single-point determination for substituent 17.
- (28) Reference 23, p 139.
- (29) A. W. Pircio and J. A. Gyls, *J. Pharmacol. Exp. Ther.*, **193**, 23 (1975).
- (30) N. F. Albertson, *J. Med. Chem.*, **18**, 619 (1975).
- (31) P. N. Craig, *Adv. Chem. Ser.*, **No. 114**, 115 (1972).
- (32) Reference 23, pp 138-141.
- (33) We wish to thank one reviewer for his remarks, summarized below. The form of correlation eq 4 suggests that the morphinans are neither substituted benzomorphans nor a new series. They appear to be somewhere in between. From eq 4 we have  $\log (1/C)_{\text{obsd(morph)}} = 0.769 \log (1/C)_{\text{calcd(benz)}} + 4.05$ . Thus the coefficient for a given substituent on a morphinan is only 0.769 of the coefficient for the same substituent on a benzomorphan. If the  $a_i$ 's were the same then the cyclohexyl would be "just another substituent"; if there was no collinearity the series would be unrelated. The 0.769 being significantly different from 1.0 indicates the "in between" character. The authors may have a tool for describing degrees of "similarity" or "congenericity."
- (34) C. Hansch in ref 31, p 28.
- (35) Reference 16, p 131.